Diagnosis of leishmaniasis based on antibodies detection represents a challenge due to cross‐reaction of sera with other infectious agents, which co‐exist in endemic areas of Leishmania sp, especially patients with Trypanosoma cruzi. This work is aimed at searching for immunogenic proteins in sera from patients with cutaneous and mucosal leishmaniasis that may be potential candidates for the development of diagnostic tests and/or vaccines that help control the infection. Total protein extracts of L. panamensis promastigotes were put in contact with sera from patients with cutaneous and mucosal leishmaniasis (immunoblots). Immunoreactive proteins were identified by mass spectrometry and bioinformatics tools. 81 proteins were identified. One of these was uniquely recognized by the sera from patients with ML but not from sera from either CL or Chagas disease patients. MS analysis of this band pointed to the putative leishmanial 3‐oxoacyl‐(Acylcarrierprotein) reductase.

中文翻译：

---

巴拿马利什曼原虫蛋白的免疫蛋白质组学表征在黏膜利什曼病的潜在临床诊断中的应用

由于血清与其他传染原的交叉反应，基于抗体检测的利什曼病诊断是一项挑战，这些病原体共存于利什曼原虫流行地区，尤其是克氏锥虫患者。这项工作的目的是在皮肤和粘膜利什曼病患者的血清中寻找免疫原性蛋白，这些蛋白可能是开发有助于控制感染的诊断测试和/或疫苗的潜在候选者。巴拿马草总蛋白提取物前鞭毛体与皮肤和粘膜利什曼病（免疫印迹）患者的血清接触。通过质谱和生物信息学工具鉴定免疫反应性蛋白质。鉴定了81种蛋白质。其中之一被 ML 患者的血清唯一识别，但不能从 CL 或南美锥虫病患者的血清中识别。对该条带的 MS 分析指向推定的利什曼原虫 3-氧代酰基-（酰基载体蛋白）还原酶。